Clinical trials: Oligometastatic Breast Carcinoma, open to volunteers
HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression.
- Trial name
- ANISE (NCT05982678)
- Testing
- Trastuzumab deruxtecan
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- The Netherlands Cancer Institute
Triple Negative Breast Cancer, Non Small Cell Lung Cancer
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
- Conditions
- Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
- Trial name
- NCT03808337
- Testing
- Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
- Where
- 12 sites in United States
- Volunteers
- 145 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
- Trial name
- NCT07578116
- Testing
- Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment
- Where
- 59 sites in United States
- Volunteers
- 562 people
- Sponsor
- SWOG Cancer Research Network
Oligometastatic Breast Carcinoma, Breast Cancer
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer.
- Conditions
- Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT05534438
- Testing
- Stereotactic body radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free…
- Trial name
- LARA (NCT04698252)
- Testing
- Radiotherapy, Surgery, Radiofrequency ablation
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Breast Cancer, MRD
Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
This is an observational clinical study of MRD as a predictor of local treatment in patients with oligometastatic breast cancer.
- Trial name
- NCT06918262
- Testing
- local treatment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Metastatic Breast Cancer, HER2-positive Breast Cancer
A Study of Surgery and Radiotherapy in People With Breast Cancer
The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic…
- Trial name
- NCT07053085
- Testing
- Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
- Where
- 7 sites in United States
- Volunteers
- 178 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Survival Outcomes
Effectiveness of Surgery for Improving Survival in Oligometastatic Breast Cancer Patients
Breast cancer is the most common malignancy in women, with stage IV disease at diagnosis in 5-10% of cases. Oligometastatic breast cancer (OMBC), defined as limited metastases (≤3-5 in ≤1-2 organs), may have better outcomes.
- Trial name
- SASI-MBC (NCT07586319)
- Testing
- surgery in accordance with current clinical guidelines, modified radical mastectomy or breast conservation surgery
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Sharif Medical Research Center
Breast Cancer, Metastatic, Metastatic Breast Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
The goal of this clinical trial is to assess Stereotactic Ablative Radiotherapy (SABR) as a method to delay a change in systemic therapy in patients with oligoprogressive ER-positive, HER2-negative advanced breast cancer.
- Trial name
- AVATARII (NCT06882499)
- Testing
- Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment
- Volunteers
- 74 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Oligometastatic Breast Carcinoma, Radiomics
FDG PET/CT Radiomics for True Oligometastatic Breast Cancer
FDG PET CT Radiomics for True Oligometastatic Breast Cancer
- Trial name
- NCT07872332
- Volunteers
- 100 people
- Sponsor
- Sohag University
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer, Metastatic Cancer
Metastases Directed Therapy for Oligometastatic Breast Cancer
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will…
- Conditions
- Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer
- Trial name
- NCT06144346
- Testing
- Stereotactic Ablative Radiation Therapy, Locoregional treatment, Standard of Care
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Egypt
Breast Cancer, Oligometastasis
stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases.
- Trial name
- ORIETTA (NCT07397585)
- Where
- 28 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Istituto Clinico Humanitas
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastasis, Metastatic Breast Cancer
The Impact of Radiotherapy on Oligometastatic Cancer
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR).
- Conditions
- Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT05933876
- Testing
- To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR)., To propose a diagnostic test to determine the effectiveness of SABR., To propose a diagnostic test for Oligometastatic Cancer (OC).
- Where
- 21 sites in Spain
- Volunteers
- 2,000 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili